Nuevolution hopes to be ready for early clinical trials in 2019

The biotech company Nuevolution will soon take its first projects to the clinic. Two drugs may be ready for clinical trials in 2019, says CEO Alex Haarh Gouliaev.

Alex Haahr Gouliaev, CEO in Nuevolution. Photo: Nuevolution

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles